Trial · NCT05693935
Results by group138
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 138
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Double-blind Period: Change in the Positive and Negative Syndrome Scale (PANSS) Total Score From Baseline to Week 8 | Double-blind: Placebo | -12.17 | 95% Confidence Interval -15.34 to -8.99 | units on a scale | |
| Double-blind Period: Change in the Positive and Negative Syndrome Scale (PANSS) Total Score From Baseline to Week 8 | Double-blind: TV-44749 318 mg | -21.91 | 95% Confidence Interval -25.13 to -18.70 | units on a scale | |
| Double-blind Period: Change in the Positive and Negative Syndrome Scale (PANSS) Total Score From Baseline to Week 8 | Double-blind: TV-44749 425 mg | -23.44 | 95% Confidence Interval -26.52 to -20.36 | units on a scale | |
| Double-blind Period: Change in the Positive and Negative Syndrome Scale (PANSS) Total Score From Baseline to Week 8 | Double-blind: TV-44749 531 mg | -21.93 | 95% Confidence Interval -25.01 to -18.85 | units on a scale | |
| Double-blind Period: Change in Clinical Global Impression-Severity (CGI-S) Scale Score From Baseline to Week 8 | Double-blind: Placebo | -0.72 | 95% Confidence Interval -0.90 to -0.54 | units on a scale | |
| Double-blind Period: Change in Clinical Global Impression-Severity (CGI-S) Scale Score From Baseline to Week 8 | Double-blind: TV-44749 318 mg | -1.25 | 95% Confidence Interval -1.43 to -1.07 | units on a scale | |
| Double-blind Period: Change in Clinical Global Impression-Severity (CGI-S) Scale Score From Baseline to Week 8 | Double-blind: TV-44749 425 mg | -1.33 | 95% Confidence Interval -1.51 to -1.15 | units on a scale | |
| Double-blind Period: Change in Clinical Global Impression-Severity (CGI-S) Scale Score From Baseline to Week 8 | Double-blind: TV-44749 531 mg | -1.19 | 95% Confidence Interval -1.36 to -1.01 | units on a scale | |
| Double-blind Period: Change in Personal and Social Performance Scale (PSP) Score From Baseline to Week 8 | Double-blind: Placebo | 5.59 | 95% Confidence Interval 3.14 to 8.04 | units on a scale | |
| Double-blind Period: Change in Personal and Social Performance Scale (PSP) Score From Baseline to Week 8 | Double-blind: TV-44749 318 mg | 10.31 | 95% Confidence Interval 7.91 to 12.72 | units on a scale | |
| Double-blind Period: Change in Personal and Social Performance Scale (PSP) Score From Baseline to Week 8 | Double-blind: TV-44749 425 mg | 8.83 | 95% Confidence Interval 6.44 to 11.22 | units on a scale | |
| Double-blind Period: Change in Personal and Social Performance Scale (PSP) Score From Baseline to Week 8 | Double-blind: TV-44749 531 mg | 10.59 | 95% Confidence Interval 8.17 to 13.02 | units on a scale | |
| Double-blind Period: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Double-blind: Placebo | Any AEs | 84 | Participants | |
| Double-blind Period: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Double-blind: TV-44749 318 mg | Any AEs | 112 | Participants | |
| Double-blind Period: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Double-blind: TV-44749 425 mg | Any AEs | 117 | Participants | |
| Double-blind Period: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Double-blind: TV-44749 531 mg | Any AEs | 126 | Participants | |
| Double-blind Period: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Double-blind: Placebo | SAEs | 3 | Participants | |
| Double-blind Period: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Double-blind: TV-44749 318 mg | SAEs | 4 | Participants | |
| Double-blind Period: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Double-blind: TV-44749 425 mg | SAEs | 1 | Participants | |
| Double-blind Period: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Double-blind: TV-44749 531 mg | SAEs | 2 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05693935/results